Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282580 · ClinicalTrials.gov registry record · Phase 1
Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01282580 is a Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01282580, a Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Research studies show that the type of fat in the diet may affect breast cancer risk. Fish oil and fish contain increased amounts of omega 3 fatty acids which appear to stop or slow down the growth and development of breast cancer cells in laboratory studies of mice and breast cancer cells. The use of omega 3 fatty acids to reduce the risk of breast cancer development in humans has not been adequately studied. Eating fish or taking fish oil may increase the amount of omega 3 in the breast, which may lower one's risk of breast cancer development. Persons in this study with do one of the following: (1) take two capsules daily of omega 3 fatty acid supplements, or (2) eat several servings of canned salmon / tuna per week for a total of three months. Amounts of omega 3 fatty acids in the body's tissues will be measured by blood tests and a small sample of breast fat as obtained by a fine needle aspiration. This study is supported by funding from the National Fisheries Institute, Food Innovation Center of The Ohio State University, and The Ohio State University Comprehensive Cancer Center.
Interventions
- DIETARY_SUPPLEMENT Lovaza-Omega 3 fatty acid capsules
- OTHER Dietary fish (canned salmon, albacore)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282580
The ClinicalTrials.gov registry entry for NCT01282580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lovaza-Omega 3 fatty acid capsules is the first listed.
NCT01282580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282580 about?
NCT01282580 is a clinical study titled "Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention". Research studies show that the type of fat in the diet may affect breast cancer risk. Fish oil and fish contain increased amounts of omega 3 fatty acids which appear to stop or slow down the growth and development of breast cancer cells in laboratory studies of mice and breast cancer cells. The use ...
What is the current status of trial NCT01282580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-07. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01282580?
The interventions under investigation include: Lovaza-Omega 3 fatty acid capsules (DIETARY_SUPPLEMENT), Dietary fish (canned salmon, albacore) (OTHER).
Who is sponsoring clinical trial NCT01282580?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.